Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments
- PMID: 11762341
Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments
Abstract
The most recent developments relating to neuroendocrine differentiation in prostate cancer are reviewed. In vivo and in vitro experimental models of neuroendocrine differentiation in prostate cancer are emphasized with a discussion of their fidelity to the actual human in vivo situation. The contribution of these models to our understanding of the process of neuroendocrine differentiation and the mechanisms by which neuroendocrine differentiation can affect prognosis is discussed. Finally, an hypothosis is proprosed integrating neuroendocrine differentiation into more traditional models of the evolution, differentiation pathways and progression of prostate cancer, particularly in the androgen independent state.
Similar articles
-
Neuroendocrine pathogenesis in adenocarcinoma of the prostate.Ann Oncol. 2001;12 Suppl 2:S145-52. doi: 10.1093/annonc/12.suppl_2.s145. Ann Oncol. 2001. PMID: 11762343 Review.
-
Neuroendocrine differentiation in prostatic carcinoma: an update.Prostate Suppl. 1998;8:74-9. Prostate Suppl. 1998. PMID: 9690666 Review.
-
Neuroendocrine differentiation in prostatic carcinoma.Scand J Urol Nephrol Suppl. 2003;(212):28-36. doi: 10.1080/03008880310006922. Scand J Urol Nephrol Suppl. 2003. PMID: 12841325 Review.
-
Human ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and interferes with androgen responsiveness in prostate cancer cells.Prostate. 2013 Aug;73(11):1241-9. doi: 10.1002/pros.22679. Epub 2013 May 8. Prostate. 2013. PMID: 23657976
-
Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status.Ann Oncol. 2001;12 Suppl 2:S141-4. doi: 10.1093/annonc/12.suppl_2.s141. Ann Oncol. 2001. PMID: 11762342 Review.
Cited by
-
Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.J Clin Pathol. 2004 Mar;57(3):321-3. doi: 10.1136/jcp.2003.010207. J Clin Pathol. 2004. PMID: 14990610 Free PMC article.
-
Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [68Ga]Ga DOTATATE PET-CT.Cancers (Basel). 2022 Dec 8;14(24):6039. doi: 10.3390/cancers14246039. Cancers (Basel). 2022. PMID: 36551525 Free PMC article.
-
T-type calcium channels blockers as new tools in cancer therapies.Pflugers Arch. 2014 Apr;466(4):801-10. doi: 10.1007/s00424-014-1444-z. Epub 2014 Jan 22. Pflugers Arch. 2014. PMID: 24449277 Review.
-
Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.Neoplasia. 2007 Nov;9(11):938-50. doi: 10.1593/neo.07562. Neoplasia. 2007. PMID: 18030362 Free PMC article.
-
Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism.J Urol. 2008 Jun;179(6):2427-34. doi: 10.1016/j.juro.2008.01.081. Epub 2008 Apr 23. J Urol. 2008. PMID: 18433784 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical